Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 13/20 | 0.40 |
| ▸ | PDE4A | P27815 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15905298 | 1.00 | GPR84 (0.40) | GPR84PDE4AHTR2CSLC6A4HTR2A | |
| SCHEMBL15905216 | 0.87 | GPR84 (0.41) | GPR84PDE4AHTR2CSLC6A4HTR2A | |
| SCHEMBL15909969 | 0.87 | GPR84 (0.41) | GPR84PDE4AHTR2CSLC6A4HTR2A | |
| SCHEMBL15905215 | 0.87 | GPR84 (0.41) | GPR84PDE4AHTR2CSLC6A4HTR2A | |
| SCHEMBL15905222 | 0.86 | GPR84 (0.46) | GPR84PDE4AKDM4EALDH1A1GAA | |
| SCHEMBL15905221 | 0.86 | GPR84 (0.46) | GPR84PDE4AKDM4EALDH1A1GAA | |
| SCHEMBL15904500 | 0.86 | PLA2G7 (0.38) | GPR84PDE4APLA2G7 | |
| SCHEMBL15904931 | 0.86 | PLA2G7 (0.38) | GPR84PDE4APLA2G7 | |
| SCHEMBL15909951 | 0.85 | PLA2G7 (0.39) | GPR84PDE4AKDM4EALDH1A1HPGD | |
| SCHEMBL15904949 | 0.85 | GPR84 (0.40) | GPR84PDE4AHTR2CSLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| EP-2948456-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014114249-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | PLA2G4A, PLA2G7, PLA2G6 | GPR84 972/4885PDE4A 329/4885HTR2C 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.